AP NEWS

Ischemia Reperfusion Injury Pipeline Review, H2 2018 - Therapeutic Assessment of 24 Companies & Drug Profile Activity - ResearchAndMarkets.com

September 25, 2018

DUBLIN--(BUSINESS WIRE)--Sep 25, 2018--The “Ischemia Reperfusion Injury - Pipeline Review, H2 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Ischemia Reperfusion Injury - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Ischemia Reperfusion Injury (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ischemia Reperfusion Injury (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Ischemia Reperfusion Injury and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 4, 5, 1, 36 and 3 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 20 and 2 molecules, respectively.

Ischemia Reperfusion Injury (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

Introduction Ischemia Reperfusion Injury - Overview Ischemia Reperfusion Injury - Therapeutics Development Ischemia Reperfusion Injury - Therapeutics Assessment Ischemia Reperfusion Injury - Companies Involved in Therapeutics Development Ischemia Reperfusion Injury - Drug Profiles Ischemia Reperfusion Injury - Dormant Projects Ischemia Reperfusion Injury - Discontinued Products Ischemia Reperfusion Injury - Product Development Milestones Appendix Akashi Therapeutics Inc Angion Biomedica Corp arGEN-X BV Balmes Transplantation SAS Boehringer Ingelheim GmbH Bolder Biotechnology Inc Catalyst Biosciences Inc Cellmid Ltd CFM Pharma Holding BV Conatus Pharmaceuticals Inc Corline Biomedical AB Gilead Sciences Inc Glucox Biotech AB Hope Pharmaceuticals Inc Ischemix Inc Lee’s Pharmaceutical Holdings Ltd LG Chem Ltd MallInckrodt Plc Nissan Chemical Industries Ltd NovelMed Therapeutics Inc Opsona Therapeutics Ltd Orexo AB Reata Pharmaceuticals Inc SBI Pharmaceuticals Co Ltd For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/fzgx38/ischemia?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180925006191/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T. Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Cardiovascular Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CARDIOLOGY PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/25/2018 05:00 PM/DISC: 09/25/2018 05:00 PM

http://www.businesswire.com/news/home/20180925006191/en

AP RADIO
Update hourly